These results suggest that CDK4/6-induced senescence in pancreatic cancer can establish emergent susceptibilities to otherwise ineffective chemo- and immunotherapies through SASP-dependent effects on the tumor vasculature and immune system [120]. The gene discussed is CDK4; the disease is familial pancreatic carcinoma.